Generics USA-based Watson Pharmaceuticals (NYSE: WPI) has confirmed that its subsidiary, Watson Laboratories, filed an Abbreviated New Drug Application with the Food and Drug Administration seeking approval to market niacin extended-release tablets, 500mg and 1,000mg, generic versions of Niaspan, a cholesterol-lowerer marketed by health care major Abbott Laboratories (NYSE: ABT). 19 March 2012